ARDX
Ardelyx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.78
+1.89%Sep 2, 2026, 06:02 UTC
Beam Therapeutics appointed Eric Foster as chief commercial officer.
Source:Aug 25, 2026, 23:50 UTC
Ardelux CFO Susan Hohenleitner sold 1,558 shares of ARDELYX common stock on August 21, 2026, in an automatic sell-to-cover transaction to satisfy tax withholding on RSU vesting, totaling approximately $6,009.
Source:Aug 25, 2026, 23:50 UTC
Joseph James Reilly, Senior Vice President and Chief Accounting Officer of Ardelyx, Inc., sold 3,982 shares of company stock for $15,358 on August 21, 2026, to cover withholding taxes upon vesting of restricted stock units.
Source:Aug 25, 2026, 23:45 UTC
James Parker Brady, Chief Human Resources Officer of Ardelyx, sold 15,136 shares of Ardelyx common stock on August 21, 2026, for a total value of $58,378, as part of an automatic sell-to-cover arrangement to cover withholding taxes upon RSU vesting.
Source:Aug 14, 2026, 14:07 UTC
SueWallSt notified investors of potential securities claims against Ardelyx, alleging that payer coverage restrictions caused an 18% drop in Ardelyx's share price on August 7, 2026.
Source:Aug 6, 2026, 22:05 UTC
Ardelyx reported second-quarter product revenue of $118 million, up 31% year-over-year, its largest quarterly total to date.
Aug 6, 2026, 22:04 UTC
Ardelyx lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased payer restrictions affecting patient access.